HCG (Human Chorionic Gonadotropin) and TRT: What It Does, Doses, and When to Use It

What Is HCG and Why Do Men on TRT Need It?

HCG is a glycoprotein hormone that shares an identical alpha subunit with LH, the pituitary signal that tells Leydig cells inside the testes to produce testosterone and support sperm maturation. When a man begins exogenous testosterone, whether via testosterone cypionate injections, testosterone enanthate, pellets, or any other form, the pituitary senses rising serum testosterone and dramatically cuts LH output. The testes go quiet. Intratesticular testosterone (ITT) drops, sperm counts fall, and the testes themselves begin to shrink in volume.

This is not a rare side effect; it is the predictable consequence of negative-feedback suppression. A 2013 review published in Translational Andrology and Urology confirmed that azoospermia or severe oligospermia occurs in roughly 90% of men using exogenous testosterone without adjunct therapy. [1] HCG prevents this by supplying the LH signal the pituitary is no longer sending.

The FDA approved human chorionic gonadotropin under brand names Pregnyl and Novarel for hypogonadotropic hypogonadism and prepubertal cryptorchidism, among other indications. [2] Prescribing it alongside a testosterone formulation to preserve testicular size and fertility is well-established in clinical practice, supported by the Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism, which states that clinicians should offer HCG to hypogonadal men who desire to maintain fertility. [3]

How HCG Works at the Cellular Level

Leydig cells express LH receptors on their surface. HCG binds these receptors with roughly the same affinity as endogenous LH, triggering a cAMP-mediated signaling cascade that activates StAR protein, which shuttles cholesterol into the mitochondrial inner membrane where the steroidogenic process begins. The end product is intratesticular testosterone, which is the primary androgen required for Sertoli cell function and spermatogenesis.

Serum testosterone and intratesticular testosterone are not the same thing. Serum levels reflect what circulates through the bloodstream after production and clearance. ITT concentrations inside the seminiferous tubules can run 50 to 100 times higher than serum levels at baseline. [4] When LH disappears due to exogenous testosterone suppression, ITT collapses even if serum testosterone reads perfectly fine on a blood panel. HCG restores ITT by directly stimulating local Leydig cell production, independent of pituitary input.

A landmark study by Coviello and colleagues (N=29, published in the Journal of Clinical Endocrinology and Metabolism, 2004) demonstrated that 500 IU of HCG administered subcutaneously every other day maintained ITT within the normal range in men whose LH had been suppressed by a gonadotropin-releasing hormone antagonist. [5] The same dose of 500 IU every other day is now a standard reference point for clinical HCG protocols in TRT.

HCG Dosing Protocols Alongside Testosterone Cypionate, Enanthate, and Other Formulations

The right HCG dose depends on the goal: fertility preservation, prevention of testicular atrophy, or full-on monotherapy for men who want to avoid exogenous testosterone entirely.

Adjunct to testosterone cypionate or testosterone enanthate (typical weekly injection protocol): The most commonly prescribed range runs 250 to 500 IU subcutaneously two to three times per week. Many clinicians schedule HCG injections on the days between testosterone injections to smooth out hormonal fluctuations. A man injecting testosterone cypionate 200 mg every two weeks (a common, though not optimal, starting point) might add 500 IU HCG on Monday, Wednesday, and Friday to maintain testicular function throughout the cycle.

Adjunct to testosterone pellets: Because pellet pharmacokinetics produce steadier testosterone levels over three to six months with no weekly injection schedule, HCG dosing follows the same 500 IU two to three times per week pattern. Some providers titrate up to 1 to 000 IU twice weekly when pellet testosterone levels run in the high-normal range, since stronger suppression of LH may require a higher replacement signal.

Adjunct to testosterone propionate: Testosterone propionate has a short half-life of roughly one to two days, meaning men using it typically inject every day or every other day. In this setting, HCG 250 IU on injection days or 250 to 500 IU every other day fits neatly into the daily subcutaneous routine.

HCG monotherapy: Some men prefer not to use exogenous testosterone, particularly younger men who want to raise serum testosterone while preserving the entire hypothalamic-pituitary-gonadal axis. HCG monotherapy doses typically range from 1,000 to 3 to 000 IU two to three times per week. Serum testosterone responses vary considerably based on baseline Leydig cell reserve. One small but well-cited trial by Lipshultz and colleagues showed that hypogonadotropic men on HCG monotherapy achieved serum testosterone in the low-normal range, but sustained high-normal levels proved difficult to maintain without adding a gonadotropin like FSH or switching to testosterone therapy directly. [6] This is why monotherapy tends to work best as a short-term bridge or diagnostic tool rather than a permanent long-term strategy.

HealthRX Clinical Decision Framework: Choosing Between HCG Adjunct and HCG Monotherapy

| Clinical Scenario | Preferred Approach | Rationale | |---|---|---| | Confirmed hypogonadism, no near-term fertility goal, testicular atrophy concern | 500 IU HCG 2-3x/week alongside testosterone | Maintains ITT and volume without replacing entire pituitary axis | | Confirmed hypogonadism, active fertility goal within 12 months | 500 IU HCG + FSH (e.g., rFSH 75 IU 3x/week) alongside testosterone OR pause TRT entirely | FSH is required for spermatogenesis; HCG alone may not restore full sperm production | | Subclinical low T, no fertility concern, prefers no exogenous T | HCG monotherapy 1,500-2 to 000 IU 3x/week, recheck T at 8 weeks | Appropriate if LH deficiency is confirmed; limited long-term data | | Secondary hypogonadism, diagnostic purpose | Single 5 to 000 IU HCG stimulation test, check T at 72 hours | Distinguishes primary from secondary/tertiary hypogonadism |

Fertility Preservation on TRT: The Evidence

The fertility question is the strongest clinical argument for adding HCG to a TRT protocol. A man in his late twenties or early thirties who starts testosterone cypionate for symptomatic hypogonadism may not be thinking about children yet, but that can change. Restoring spermatogenesis after prolonged testosterone-induced suppression is possible but takes time and is not guaranteed.

A study by Shankara-Narayana and colleagues (N=100, 2019, Journal of Clinical Endocrinology and Metabolism) found that median time to sperm recovery after cessation of exogenous testosterone was six months, but roughly 10% of men had not recovered adequate counts at 12 months. [7] Starting HCG from day one of TRT significantly reduces this risk by keeping the Sertoli-cell support environment active throughout therapy.

The Endocrine Society's guideline is explicit on this point: "We suggest using hCG (1,500-2 to 000 IU every other day) in testosterone-deficient men desiring fertility." [3] That phrasing comes directly from the 2018 document and applies whether the man is just beginning TRT or is already established on testosterone enanthate or cypionate.

For men who need to maximize sperm counts for an assisted reproduction cycle, adding recombinant FSH (rFSH 75 IU subcutaneously three times per week) to the HCG protocol has been shown to improve total motile sperm count further than HCG alone. A Cochrane review of gonadotropin regimens for male infertility in hypogonadotropic hypogonadism found a pregnancy rate of approximately 70-80% with combined HCG plus FSH versus considerably lower rates with either agent alone. [8]

Managing Side Effects of HCG in Men

HCG stimulates Leydig cells to produce testosterone, and Leydig cells also have aromatase activity, meaning more testosterone substrate means more estradiol conversion. The most frequently reported side effect in men using HCG is elevated estradiol, which can cause water retention, mood changes, and gynecomastia in susceptible individuals.

Monitoring serum estradiol (sensitive or LC-MS/MS assay, not standard immunoassay) every six to eight weeks when starting or adjusting HCG dose lets the prescriber decide whether a low-dose aromatase inhibitor like anastrozole 0.25 to 0.5 mg twice weekly is warranted. Blanket aromatase inhibitor use is not recommended; the goal is to keep estradiol in the 20-40 pg/mL range, not to suppress it entirely. [9]

Other reported effects include:

• Acne flares, due to increased androgen production from Leydig stimulation
• Testicular pain or discomfort during the first two to four weeks, usually transient
• Antibody formation against HCG with very long-term use, though clinically significant tachyphylaxis is rare at standard TRT adjunct doses
• Polycythemia in some men, because the additional intratesticular testosterone production adds to the total androgen load; hematocrit should be checked alongside standard TRT monitoring

The FDA removed compounded HCG from the market in 2020, ruling it was not essentially a copy of an FDA-approved biologic. [10] As of that ruling, men need pharmaceutical-grade HCG (Pregnyl, Novarel, or the FDA-approved brand) rather than compounded preparations. Some telehealth providers have pivoted to kisspeptin analogs or enclomiphene as alternatives when branded HCG is cost-prohibitive, though the evidence base for those alternatives is thinner.

HCG for Diagnostic Use: Differentiating Primary from Secondary Hypogonadism

Before starting any testosterone formulation, a clinician needs to know whether low serum testosterone stems from a failing testis (primary hypogonadism) or a failing hypothalamic-pituitary signal (secondary or tertiary hypogonadism). The standard diagnostic pathway checks serum LH and FSH alongside total testosterone, but in ambiguous cases a formal HCG stimulation test provides definitive information.

The protocol: a single intramuscular injection of 5 to 000 IU of HCG, with serum testosterone drawn at baseline and again at 72 and 96 hours. Men with intact Leydig cell reserve (secondary hypogonadism) show a strong rise in testosterone of at least 150% above baseline. Men whose testes cannot respond (primary hypogonadism) show a blunted or absent rise. [11] This test directly determines whether the problem is upstream (pituitary or hypothalamic) or at the gonadal level, a distinction that shapes the treatment plan significantly.

Secondary hypogonadism with intact testicular function is exactly the population most likely to benefit from HCG monotherapy or HCG as a bridge while lifestyle factors (obesity, opioid use, hyperprolactinemia) are addressed. Primary hypogonadism, by contrast, means the testes cannot produce meaningful testosterone regardless of gonadotropin stimulation, so exogenous testosterone replacement with testosterone cypionate or enanthate becomes the straightforward choice.

Reconstituting and Injecting HCG: Practical Steps

Pharmaceutical HCG ships as a lyophilized (freeze-dried) powder in a vial, typically 10 to 000 IU per vial, accompanied by a separate vial of bacteriostatic water (0.9% benzyl alcohol). Reconstitution requires careful dilution to hit the intended concentration.

A standard approach: inject 10 mL of bacteriostatic water into the 10 to 000 IU powder vial, producing a concentration of 1 to 000 IU per mL. A 500 IU dose then equals 0.5 mL drawn in an insulin syringe. Reconstituted HCG should be stored refrigerated at 2-8 degrees Celsius and used within 60 days. Do not freeze the reconstituted solution; freezing degrades the protein structure.

Subcutaneous injection into the abdomen or upper thigh, using a 29 or 31 gauge half-inch needle, is the standard delivery for TRT-adjunct HCG. Intramuscular injection (deltoid or gluteal muscle) is also effective but unnecessary at the small volumes typical of a 250-500 IU dose.

Monitoring Labs on a Combined Testosterone and HCG Protocol

A complete monitoring panel at baseline and at eight to twelve weeks after starting or adjusting HCG includes:

• Total testosterone and free testosterone (draw on a day when the previous testosterone injection was at its trough, typically 5-7 days after testosterone cypionate or enanthate injection)
• Estradiol (sensitive LC-MS/MS assay)
• LH and FSH (to confirm degree of suppression and guide dose adjustments)
• Hematocrit and hemoglobin (HCG increases endogenous androgen production, adding to polycythemia risk)
• PSA in men 40 or older, per AUA and Endocrine Society guidance
• Semen analysis at three to six months for men with fertility goals, since spermatogenesis takes approximately 74 days (one full spermatogenic cycle) to reflect a medication change [12]

The American Urological Association 2018 guideline on testosterone deficiency recommends checking testosterone and hematocrit at three to six months, then annually once stable. [13] HCG does not change those intervals but adds estradiol monitoring given its aromatase-stimulating effect.

HCG vs. Alternative Approaches to Preserving Testicular Function

Not every man is a candidate for HCG or can afford branded pharmaceutical costs. Two other options come up frequently in practice.

Clomiphene citrate (clomid): An oral selective estrogen receptor modulator that blocks estrogen negative feedback at the hypothalamus, raising endogenous LH and FSH. A randomized trial by Katz and colleagues (N=20, 2012) showed clomiphene 25 mg every other day raised serum testosterone in hypogonadal men comparably to testosterone replacement, while preserving gonadotropin secretion. [14] The limitation: clomiphene raises LH only if the hypothalamic-pituitary axis is intact. Men with pituitary damage or prolonged suppression from testosterone use may not respond. HCG bypasses the entire axis by acting directly on the testes.

Enclomiphene citrate: The active trans-isomer of clomiphene, with fewer estrogenic effects from the cis-isomer (zuclomiphene). Early Phase II data showed promise, but it has not yet received FDA approval for hypogonadism as of 2025. [15] Some clinicians use it off-label.

For men already established on testosterone cypionate or enanthate who want to preserve or restore fertility, the evidence most strongly supports HCG (with or without FSH) over clomiphene, because the testicular response is direct and dose-predictable.